Dopamine Receptor Agonist Combined with Levodopa and Benserazide Hydrochloride Tablets in Patients with Parkinson's Disease

Cardiovascular system symptoms are closely related to the decrease of motor function, quality of life, survival rate and mortality rate of patients with Parkinson's disease. Therefore, early detection and diagnosis of cardiovascular function in patients with Parkinson's disease is very important. The purpose of this study is to study the changes of symptoms of patients with Parkinson's disease treated with levodopa and benserazide hydrochloride tablets and dopamine receptor agonists in order to judge the situation of patients with Parkinson's disease treated, and to explore the difference of clinical manifestations of the long-term curative effect and find a more effective treatment plan. The combination of dopamine receptor agonist and levodopa and benserazide hydrochloride tablets can not only increase the supplement level of dopamine in Parkinson's patients, but also has the advantages of long acting time and quick acting. It is necessary to let Parkinson's patients take less levodopa and benserazide hydrochloride tablets to avoid certain side effects and improve the clinical efficacy. The results of the experimental control group can be seen that the effect of dopamine receptor agonists combined with levodopa and benserazide hydrochloride tablets on Parkinson's disease patients increased from 60% to 75%.